Skip to search formSkip to main contentSkip to account menu

ertumaxomab

Known as: Anti-CD3 x anti-HER-2-neu Bispecific Monoclonal Antibody, CD3-HER2neu MOAB, MOAB anti-CD3 x anti-HER-2-neu 
A murine monoclonal antibody with two antigen-recognition sites: one for CD3, an antigen expressed on mature T cells, and one for HER-2-neu, a tumor… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Interim analysis of a phase I/II open label, dose-escalating study to investigate safety, tolerability, and preliminary efficacy of the trifunctional anti-HER2/neu x anti-CD3 antibody ertumaxomab in…
3055 Background: Ertumaxomab (ertu) is a bispecific, trifunctional antibody (ab) targeting HER2/neu, CD3 and the Fcγ-receptors I… 
2012
2012
Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling
Background: The trifunctional antibody ertumaxomab bivalently targets the human epidermal growth factor receptor 2 (Her2) on… 
2011
2011
Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment
BackgroundTrifunctional antibodies, such as catumaxomab (anti-EpCAM×anti-CD3) and ertumaxomab (anti-HER-2/neu×anti-CD3… 
2010
2010
Abstract P3-14-21: Phase II Study of Single Agent Trifunctional Antibody Ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 Low Expressing Hormone-Refractory Advanced Breast Cancer Patients (ABC)
Background: Ertumaxomab is an intact bispecific trifunctional antibody targeting HER-2 and CD3 as well as activating Fc… 
2010
2010
Abstract 3481: Establishment of preclinical models to identify clinically useful combinations of trifunctional antibodies with chemotherapy
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC The trifunctional bispecific antibodies… 
2010
2010
Langzeit-Tumorstabilisation einer Her-2-neu positiven, metastasierten Mammakarzinompatientin unter Lapatinib und Capecitabin
2010
2010
Langzeitüberleben einer Her-2-neu-positiven Mammakarzinompatientin unter Lapatinib und Capecitabin trotz zahlreichen Vortherapien
2008
2008
Effect on low HER2 (1+) expressing tumor cells of the trifunctional antibody ertumaxomab
3071 Background: Her2/neu has become an important therapeutic target for treatment of breast cancer with overexpressed Her2/neu… 
2008
2008
Highly effective elimination of low Her2 (1+) expressing tumor cells by trifunctional antibody ertumaxomab
2405 Her2 has become an important therapeutic target for antibody-directed treatment of breast cancer with overexpressed Her2 (3… 
2006
2006
Phase I Trial of theTrifunctional Anti-HER 2 Anti-CD 3 Antibody Ertumaxomab in Metastatic Breast Cancer
Purpose: Ertumaxomab is an intact bispecific antibody targeting HER2/neu and CD3 with selective binding to activatory Fcg type I… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)